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Background: MiRNA-21 was previously reported to be up-regulated in many kinds of cancer. In the present study,
we want to investigate the potential role of miRNA-21 in non-small cell lung cancer.
Materials and methods: Expression of miRNA-21 was detected in 60 non-small cell lung cancer (NSCLC) samples
and adjacent histologically normal tissue using RT-qPCR, Correlation between miRNA-21 expression and
clinicopathological features of NSCLC was analyzed using statistical software. The effect of miRNA-21 expression on
the growth and apoptosis of A549 cells induced by irradiation was examined.
Results: miRNA-21 expression increased in non-small cell lung cancer. Expression of miRNA-21 was positively
associated with lymph node metastasis, clinical stage and poor prognosis. Multivariate Cox regression analysis
showed that miRNA-21 was an independent prognostic factor for patients. Down-regulation of miRNA-21 inhibited
proliferation and cell cycle progress of A549 cells and sensitized cells to radiation. Decreased miRNA-21 expression
promoted the apoptosis of A549 cells induced by irradiation.
Conclusions: miRNA-21 may be considered as a potential novel target for future development of specific
therapeutic interventions in NSCLC.
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Worldwide there are >1,600,000 new cases of lung
cancer and >1,370,000 attributable deaths each year,
ranking it as a leading cause of cancer mortality. In
China lung cancer is the highest incidence of malignant
tumor and the age-standardized incidence rate and mor-
tality rate adjusted for the world standard population are
both higher than the average levels worldwide [1].
MicroRNAs (miRNAs) are a class of small, evolutionary
conserved RNA molecules that negatively regulate gene
expression at the post-transcriptional level. The discovery
of these small non-coding transcripts broadened our
understanding of the mechanisms that regulate gene
expression, added an entirely novel level of regulatory
control. miRNAs consist of 18–25 nucleotides and are a
class of endogenous ribo-regulators that modulate gene
expression via the RNA interference (RNAi) pathway.* Correspondence: wxc3188@126.com
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distribution, and reproduction in any mediumPrimary transcripts of miRNAs (pri-miRNA) are gene-
rated by RNA polymerase II [2], after which they are
sequentially processed by RNase III class enzymes, Drosha
and Dicer, to first produce ~70 nt-long intermediate hair-
pin structures (pre-miRNAs) and finally the mature
miRNAs. MiRNAs act by base-pairing with their target
mRNAs through perfect or nearly perfect complementa-
rity at the 3′ untranslated regions (UTRs) of the target
mRNAs leading to their translational repression and/or
direct cleavage [3,4]. However, in some cases miRNAs can
enhance mRNA translation. MiRNA-10a was found to
bind the 5′UTR of ribosomal protein mRNAs and enhan-
ced their translation, and some miRNAs were shown to
switch from translation repression to promotion in a cell
cycle-dependent manner [5,6]. Human miRNAs have been
reported and a number of these have been shown to play
normal physiologic roles in cell proliferation, apoptosis,
and differentiation [7]. In addition, studies have showed
that miRNAs contributed to oncogenesis by promoting
the expression of oncogenes or by inhibiting tumortral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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for cancer diagnosis and prognosis [8].
MiRNA-21was one of the first miRNAs to be identified
as transcribed by RNA polymerase II, which subsequently
has been identified as a major driver of miRNA trans-
cription. The gene coding for pri-miRNA-21 (primary
transcript containing miRNA-21) is located within the
intronic region of the TMEM49 gene. Despite pri-
miRNA-21 and TMEM49 are overlapping genes in the
same direction of transcription, pri-miRNA-21 is inde-
pendently transcribed by its own promoter regions and
terminated with its own poly (A) tail. After transcription,
pri-miRNA-21 is finally processed into mature miRNA-21
[9]. MiRNA-21 has been shown to be overexpressed in
multiple malignancies including pancreatic cancer [10,11],
esophageal cancer [12], lung cancer [13], and colon cancer
[14]. This miRNA has been linked to tumor aggression
and carcinogenesis, in part, by preventing apoptosis and,
thus, functioning as an oncogene [15,16]. In the present
study, we examined the expression of miRNA-21 in non-
small cell lung cancer (NSCLC) and explored its effects
on radio-sensitivity of NSCLC. The results indicated that
miRNA-21 was overexpressed, and was associated with
lymph node metastasis and poor prognosis of NSCLC.




Sixty fresh tissue samples, containing NSCLC and adja-
cent histologically normal tissue, were procured from
surgical resection specimens collected by the Department
of Tumor Medicine, Henan People’s Hospital from 2001
to 2007. Primary tumor regions and corresponding
histologically normal tissues from the same patients were
separated by experienced pathologists, and immediately
stored in liquid nitrogen (–193°C) until use. All patients
were received no treatment before surgery and signed
informed consent forms for sample collection. Use of
patient samples comprising tumor and adjacent histologi-
cally normal tissues was approved by our institutional
ethics committee of Radiation Medicine Institute. For all
the samples, clinic-pathological information (smoking,
age, gender, pathological subtype, TNM classification,
tumor stage, lymph node stage, differentiation status and
the duration of survival after surgery) was available.
Cells culture and ionizing radiation
Lung cancer A549 cells were cultured in RPMI 1640
(Invitrogen) supplemented with 10% fetal bovine serum
(FBS) at 37˚C under 5% CO2 in a humidified incubator.
Cells were exposed different dose of irradiation in a JL
Shepherd Model 143 137Cesium γ-irradiated at a rate of
2.4 Gy/min.RNA extraction
Total RNA was extracted from NSCLC tissue and its
corresponding normal tissue using the Absolutely RNA™
RT-PCR Miniprep kit (Stratagene), according to the
manufacturer’s instructions. Total RNA concentration
was adjusted to 2 ng/μl using a spectrophotometer.
Real-time RT-PCR quantification of miRNA-21
Taq Man miRNA assays (ABI PRISM) used the stem-loop
method to detect expression levels of mature miRNA-21
[17]. For reverse transcription (RT) reactions, 10 ng total
RNA was used in each reaction (5 μl) and mixed with RT
primer (3 μl). RT reactions were carried out at 16°C for
30 min, 42°C for 30 min and 85°C for 5 min, then
maintained at 4°C. Following RT reactions, 1.5 μl cDNA
was used for a polymerase chain reaction (PCR) along
with Taq Man primers (2 μl). PCR was conducted at 95°C
for 10 min followed by 40 cycles at 95°C for 15 sec and at
60°C for 60 sec in the ABI 7500 real-time PCR system.
Real-time PCR results were analyzed and expressed as
relative miRNA expression of the threshold cycle (CT)
values. RT and PCR primers for miRNA-21 were
purchased from ABI PRISM. U6B was used for
normalization. Relative expression level between different
treatments were then calculated using the following equa-
tion: = 2- (ΔCtsample-ΔCt control) [17]. A two-fold change in
either direction was considered to be significant.
miRNA transfection and northern blots
The miRNA-21 RNAi vector was constructed by cloning of
annealed oligonucleotides that contained the pre-miRNA-
21 sequence into the pSuppressorNeo expression vector. A
scrambled sequence without significant homology to any
rat, mouse or human gene was used as a negative control
(scrambled group). Transfection was performed using
Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA) according
to the manufacturer’s instructions. Briefly, one day before
transfection, cells was plating in 500 μl of growth medium
without antibiotics so that cells will be 90-95% confluent
at the time of transfection. 50 nM DNA was diluted in
50 μl medium without serum. Mixing Lipofectamine™
2000 gently before use, then diluting 5 μl in 50 μl medium.
Incubating for 5 min at room temperature. Then the di-
luted DNA was combined with the diluted Lipofectamine
2000. Mixing gently and incubating for 20 min at room
temperature. Adding the complexes to each well containg
cells and medium. The plate was mixed gently by rocking
back and forth. Incubating the cells at 37°C in CO2
incubator for 48 h. Then northern blots assay was used to
confirm the knock-down effects of miRNA-21 expression.
For miRNA northern blots, 15 μg of total RNA
were separated on 15% denaturing polyacrylamide gels,
electrotransferred onto GeneScreen Plus membranes
(PerkinElmer), and hybridized using UltraHyb-Oligo
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mature miRNA-21(5′-aucgaauagucugacuacaacu-3′) were
end-labeled with T4 Kinase (Invitrogen) and used as
probes. Hybridization was performed at 42°C overnight
and membranes washed twice in 0.1×SSPE and 0.1%
SDS at 42°C for 15 min each. Membranes were then
exposed to a storage phosphor screen (GE Healthcare
Bio-Sciences) for 8 h and imaged using a Typhoon 9410
Variable Mode Imager (GE Healthcare Bio-Sciences).
Saved images were cropped using Photoshop 6.0 (Adobe
Systems).
Cell proliferation assay
Four hundred cells were aliquoted into each well of a 6-
well plate in triplicate and exposed to γ-ray with different
dose of irradiation. After 10 days of incubation, theFigure 1 Expression of miRNA-21in NSCLC and its correlation with pr
patients detected by real-time RT-PCR. MiRNA-21 expression level was high
(p<0.0001). U6 snRNA was used as an internal control. Horizontal line, mea
NSCLC patients sub-grouped as miRNA-21 low or high expression. The pro
that of patients with miRNA-21 low patients (p=0.007).colonies were stained with the Giemsa stain and a
minimum of 50 viable cells were counted. Quantity One
software (version 4.6.2) was used to analyze the results.
The effects of miRNA-21 expression on A549 cell pro-
liferation were assessed using the Cell Counting Kit-8
(CCK-8, Dojindo, Japan). Briefly, the cells were plated in
96-well plates. Cells was irradiated with 6 Gy γ-ray in
48 hours after transfection. Then CCK-8 (10 μl) was
added to each well at various time points and incubated at
37°C for 1.5 h. Cells were harvest at 1, 2, 3, 4, 5 and 6 day
after irradiation, respectively. The absorbance at 450 nm
was measured using a microplate spectrophotometer.
Cell cycle assay
Cell cycle profiles were examined using flow cytometry.
Briefly, cell monolayers were washed with phosphate-ognosis of patients. A, miRNA-21 expression in NSCLC cancer
er in NSCLC tissue than in corresponding non-cancerous tissue.
n value of each group. *** p<0.0001. B, Kaplan-Meier survival curve of
gnosis of patients with high miRNA-21 was significantly shorter than
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ice-cold PBS. Cells were then gently pelleted by centrifu-
gation (300×g for 5 min at 4°C), the supernatant was
removed and the cells were fixed and permeabilized by
the dropwise addition of 70% ethanol at -20°C while
vortexing. Fixed cells were washed with PBS and incu-
bated in the dark for 30 min with a propidium iodide
(PI) staining solution containing 50 μg/ml propidium
iodide (PI) and 100 μg/ml RNase A in PBS. The
propidium iodide fluorescence per cell was measured
with a Flow Cytometer (BD, Franklin Lakes, NJ) equip-
ped with a 488 nm argon laser. The width (FL2W) and
area (FL2A) of the PI fluorescence per cell were
recorded for at least 10,000 cells per sample. Histograms
of the PI intensities were plotted. The percentage of cells
in each phase of the cell cycle was analyzed using
ModFit software.Cell apoptosis assay
Cells were harvested 8 hours post irradiation with a dose
of 0, 4 and 8 Gy for apoptosis detection using the annexin
V-FITC apoptosis detection kit (Sigma) and subsequently







Low (n=19) High (n=41) P
Age, years
≥60 38 10 28 0.242
<60 22 9 13
Sex
Male 34 12 22 0.490
Female 26 7 19
SmokingWestern blot analysis
Whole cell extracts were prepared from cultured cells by
homogenizing cells in a lysis buffer (10 mM Tris–HCl
(pH 7.5), 150 mM NaCl, 1% NP40) containing a cocktail
of protease inhibitors. After centrifugation at 15,000 RCF
for 30 min at 4°C, supernatants were recovered and used
for immunoblot analysis. The proteins were separated by
SDS-PAGE and then transferred to polyvinylidene difluo-
ride (PVDF) membranes (Millipore). Blots were blocked
and then probed with antibodies against Pro-caspase3
(1:500 dilution, Santa Cruz), PARP (1:500, Santa Cruz)
and β-actin(1:1000, Santa Cruz). After washing, the blots
were incubated with horseradish peroxidase-conjugated
secondary antibodies and visualized by super ECL detec-
tion reagent (Applygen, Beijing, China).Smoking 33 11 22 0.759
No smoking 27 8 19
Lymph node metastasis
N0 29 15 14 0.005
N1 31 4 27
Stage
I + II 29 14 15 0.007
III +IV 31 5 26
Grade
G1+ G2 32 10 22 0.941
G3 28 9 19Statistical analysis
All statistical analysis was performed using SPSS16.0
software. Results were statistically evaluated using Chi-
square test. Patient survival curves were estimated by
the Kaplan-Meier method. The median miRNA intensity
value of the initial training cohort was used as the cut
point in Kaplan-Meier survival analysis, and patients
were categorized into groups with high (above median)
or low (below median) expression. The joint effect of
covariables was examined using the Cox Proportional
Hazard Regression Model. p < 0.05 was considered to be
statistically significant.Results
MiRNA-21 expression level was higher in NSCLC tissue
than in corresponding non-cancerous tissue
Expression of miRNA-21 was detected in 60 NSCLC sam-
ples and adjacent histologically normal tissues using RT-
qPCR, and its expression was normalized to that of the
control U6B small nuclear RNA gene (RNU6B). Results
showed miRNA-21 expression levels were significantly
higher in NSCLC tissues than that in corresponding non-
cancerous tissues (Figure 1A). Statistical analysis showed
that overexpression of miRNA-21 was associated with
lymph node metastasis and clinical stage of NSCLC
(Table 1). To determine the association between miRNA-
21 expression and prognosis, Kaplan–Meier curves for
overall survival was plotted. Significant difference was
observed in NSCLC patient survival according to miRNA-
21 expression in tumor tissues. The survival rate of patients
with low miRNA-21 expression was higher than that of
patients with high miRNA-21 expression (p=0.007)
(Figure 1B). Multivariate Cox regression analysis showed
that miRNA-21 expression (p=0.032), regional lymph node
metastasis (p=0.015) and clinical stage (p=0.004) were inde-
pendent prognostic factors for NSCLC patients (Table 2).
Knock-down of miRNA-21 promoted the radio-sensitivity
of A549 cells
MiRNA-21 expression was examined the in A549 cells
at 0, 2, 4, 6 and 8 hours after radiation with a dose of
Table 2 Postoperative survival of patients in relation to clinicopathological characteristics and microRNA expression
analyzed by the Cox proportional hazard regression model in 60 cases
Variables Univariate analysis Multivariate analysis
Hazard ratio (95% CI) p Hazard ratio (95% CI) p
Smoking +/- 1.014(0.385-2.668) 0.978 1.351(0.477-3.831) 0.571
Age ≥60 1.111(0.528-2.338) 0.456 1.053(0.478-2.324) 0.897
Sex M/F 1.265(0.481-3.331) 0.634 1.710(0.595-4.915) 0.319
LN metastasis +/- 2.389(1.099-5.196) 0.025 2.045(1.072-3.513) 0.015
TNM I+II/III 1.794(1.131-2.845) 0.003 4.021(1.764-6.462) 0.004
Differentitation Well+mod/poor 1.283(0.656-2.508) 0.654 1.687(0.734-3.879) 0.218
miRNA-21 Low/High 2.827(1.274-6.275) 0.011 2.103(0.695-3.078) 0.032
LN Lymph node, TNM Stage of Tumor, Regional Lymph node and Metastasis; CI Confidence Interval.
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ation. Its level increased after 4 hours, showing that
miRNA-21 may have effects on the radiation response of
A549 cells (Figure 2A).Knock down miRNA-21 inhibited growth of A549 cells
induced by gamma radiation
To determine whether miRNA-21 actually enhances the
sensitivity of A549 cell lines to radiation-induced death,
A549 cells were transfected with miRNA-21 RNAi and
scrambled RNAi vector. 48 hours after transfection, the
cells were exposed to various doses of IR (0, 2, 4, 6 and
8 Gy) at a rate of 2.4Gy/min. Then clonogenic assay was
performed. Results showed that the survival fraction of
miRNA-21 knock-down cells was significantly lower
than that of control groups (Figure 2C), showing a
correlation between miRNA-21 expression and radio-
sensitivity of A549 cells to gamma radiation.
We also examined the effects of miRNA-21 expression
on cellular proliferation after exposed to 6 Gy IR. The
results showed that knock down of miRNA-21 inhibited
the growth of A549 cells (Figure 3A and B).Figure 2 Effects of miRNA-21 expression on radio-sensitivity of
NSCLC cell. A, Elevated miRNA-21 was observed after γ- ray
radiation with a dose of 6 Gy, and its level was highest at 8 hours.
B, A549 cells were transfected with miRNA-21 RNAi and scrambled
RNAi vector. Expression of miRNA-21 was detected in 48 hours after
transfection miRNA-21 level decreased in RNAi cells. C, Cells were
exposed to various doses of IR (0 Gy, 2 Gy, 4 Gy, 6 Gy and 8 Gy) at a
rate of 2.4 Gy/min 48 hours after transfection, then clonogenic assay
was performed. Knock-down of miRNA-21 promoted the radio-
sensitivity of A549 cells,*p<0.05.Knock down miRNA-21 affected the cell cycle of A549
cells induced by gamma radiation
Cell cycle analysis was executed to determine whether
the effect of miRNA-21 on cell proliferation was due to
cell cycle alterations. A549 cells were transfected with
miRNA-21 RNAi and scrambled RNAi vector. 48 hours
after transfection, cells were exposed to 6 Gy γ-ray.
Then these cells were harvested and cell cycle was ex-
amined by flow cytometry. The result showed that as
comparing to the control group, the percentage of cells
at G1 phase was significantly increased, whereas the
population of cells at S phase significantly decreased in
miRNA-21 knock down group(p<0.01) (Figure 3C).
These results indicated that decreased expression of
miRNA-21 induced G1 cell cycle arrest in A549 cells.
Figure 3 Down-regulation of miRNA-21 inhibited A549 cell proliferation and cycle progress after IR. A, A549 cells were transfected with
miRNA-21 RNAi and scrambled RNAi vector. Expression of miRNA-21 was detected in 48 hours after transfection. miRNA-21 level decreased in
RNAi cells. B, Statistical plots of 3 independent cell growth assay.A549 cells were irradiated with 6 Gy γ-ray in 48 h after transfection. Then cells
were harvest at 1, 2, 3, 4, 5 and 6 day after irradiation, respectively and cell growth was monitored. The proliferation ability of miRNA-21 knock
down cells was lower than that of control groups. C, Cells were exposed to 6 Gy γ-ray in 48 hours after transfection. Then these cells were
harvested and cell cycle was examined by flow cytometry. Percentage of cells in different cell cycle phases was plotted and results were
represented as mean ± s.d. Comparing with the control groups, the percentage of cells at G1 phase was significantly increased, whereas the
population of cells at S phase significantly decreased in miRNA-21 knock down group (p<0.01).
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cells induced by gamma radiation
We next explored its role in the apoptosis of NSCLC
cells induced by irradiation. A549 cells were transfected
with miRNA-21 RNAi and scrambled RNAi vector,
48 hours later, these cells were exposed to various doses
of IR (0, 4 and 8 Gy) at a rate of 2.4Gy/min. As shown
in Figure 4A, miRNA-21 level decreased after trans-
fected with miRNA-21 RNAi vector. The percentage of
apoptosis cells in miRNA-21 knock-down group wassignificantly higher than that of parental and control
group at the dose 4 and 8 Gy (p<0.05). At the dose of
0 Gy, no significantly different was found among these
three groups in the percentage of apoptosis cells
(Figure 4B). We then examined the effects of miRNA-21
knockdown on caspase 3 activity (a central mediator of
apoptosis) after 4 Gy IR. Decreased miRNA-21 ex-
pression markedly increased the activity of caspase 3
compared to parental or scrambled RNAi controls
(Figure 4C).
Figure 4 Effects of miRNA-21 knock down on the apoptosis of
A549 cells induced by gamma radiation. A, Expression of miRNA-
21 decreased in miRNA-21 RNAi cells. B, Detection of apoptosis
induced by various dose of irradiation through annexin V-FITC/PI
staining and results were ploted as mean ± s.d. from triplicate
experiments. p<0.01 vs parental and scrambled RNAi groups.
Percentage of apoptosis in miRNA-21 knock-down group were
significantly higher than that of control groups in both 4 and 8 Gy
dose. C, Down-regulation of miRNA-21 led to increased activation of
Caspase 3, as evident from increased levels of Cleaved-PARP.
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Studies have shown that miRNAs expression fingerprints
correlated with clinical and biological characteristics of
tumours, including tissue type, differentiation, aggression,
response to therapy and prognosis [18]. A large amount of
diagnostic information was encoded in a relatively small
number of miRNAs. Amplification or overexpression of
an oncogenic miRNA could eliminate the expression of a
miRNA-target tumor suppressor gene, and result in
cancer progression [19]. MiRNA-21 has been classed as
an oncogenic miRNA and its overexpression could lead to
tumor development and progression. Up-regulation of
miRNA-21 has been found in numerous human cancers.
Markou et al. found overexpression of mature miRNA-21was an independent negative prognostic factor for overall
survival in NSCLC patients [20]. Wang et al. found that
the level of miRNA-21 expression was higher in NSCLC
serum samples than in control serum samples. High
serum miRNA-21 was significantly correlated with tumor-
node metastases stage and lymph node metastasis of
NSCLC patients. The 3-year actuarial overall survival rate
in NSCLC patients with high serum miRNA-21 expres-
sion was significantly shorter than those with low serum
miRNA-21 expression. Moreover, serum miRNA-21 ex-
pression was an independent prognostic factor for NSCLC
patients [21]. Shen et al. also reported that altered expres-
sion of the miRNAs (miRNA-21, -126,-201 and 486-5p) in
plasma would provide potential blood-based biomarkers
for NSCLC [22]. In the present study, we found that
miRNA-21 expression levels were significantly higher in
NSCLC tissues and its expression was associated with
lymph node metastasis and clinical stage. In addition,
miRNA-21 also was an independent prognostic factor for
NSCLC patients. Both our and others results showed that
miRNA-21 might be a useful diagnostic and prognostic
marker for NSCLC patients. A non-transcriptional me-
chanism for miRNA-21 upregulation implying gene amp-
lification, rather than promoter hyper-activation, has been
proposed [23]. However, most of the available data suggest
that miRNA-21 expression is maintained by transcrip-
tional and post-transcriptional regulation [24].
Although many studies have explored the role of
miRNA-21 in cancer, there are few reports about the
relationship between miRNA-21 expression and radio-
sensitivity of cancer. Want el al detected the expression
profile of miRNA in postoperative radiotherapy sensi-
tivity and resistant patients of NSCLC. They found
miRNA-21 was greatly down-regulated in radiotherapy
sensitive patients [25]. Zhu et al. reported that miRNA-
21 was the only one that increased 6 folds in high-LET
(low linear energy transfer) radiation promoted mouse
liver tumors when compared with that in the non-
irradiated liver tissues. They also showed that miRNA-
21 was up-regulated in human or mouse hepatocytes
after exposure to radiation, as well as in liver tissues
derived from whole body irradiated mice [26]. These
results suggested that miRNA-21 expression may have
effects on the radio-sensitivity of tumors. Given that
radiation therapy is one of the most important methods
for NSCLC treatment, we examined the effects of
miRNA-21 expression on radio-sensitivity of A549 cells
in the present study. The clonogenic formation assay
showed that down-regulation of miRNA-21 promoted
the radio-sensitivity of A549 cells. Moreover, decreased
miRNA-21 level inhibited proliferation and cell cycle
progress of A549 cells after IR. We did not further
explore the potential mechanism. But it has been
reported that miRNA-21 had the ability to suppress the
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miRNA-21 also directly represses the expression of the
tumor suppressor gene tropomyosin 1 (TPM1) [29].
These mechanisms may also be function in the condi-
tion of IR.
We also found that decreased miRNA-21 expression
promoted the apoptosis of A549 cells induced by irradi-
ation. At the molecular level, caspase-3 was activated in
miRNA-21 knock down cells. It has been reported that
down regulation of miRNA-21 in clultured glioblastoma
cells triggered activation of caspases and led to increased
apoptotic cell death [15]. These data suggested that
aberrantly expressed miRNA-21 may contribute to the
malignant phenotype and radio-resistance of tumors by
blocking expression of critical apoptosis-related genes.
Conclusion
In conclusion, our results revealed that miRNA-21 was
overexpressed in NSCLC tumors. Increased expression of
miRNA-21 was strongly associated with lymph node me-
tastasis and poor prognosis. In addition, Down-regulation
of miRNA-21 inhibited proliferation and cell cycle
progress of A549 cells and sensitized cells to radiation.
Our findings provide a new role of miRNA-21 in NSCLC,
and it may be considered as a potential novel target for
future development of specific therapeutic interventions
in NSCLC.
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